1. MARKETS
  2. SECTOR : DIVERSIFIED CONSUMER SERVICES
  3. INDUSTRY : HEALTHCARE SERVICES
  4. BIOCEPT INC
Biocept Inc
XNAS: BIOC

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Biocept Inc is on 19 Oct 2026 for the purpose of Biocept Inc Third Quarter Earnings Results for 2026See details

Biocept Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Biocept Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEGATIVE

    Quarterly Revenue Biocept Inc Jun-2023 Quarterly Revenue is $1 Million which is growth of -94.4% YoY.

  • POSITIVE

    Quarterly Net Profit Biocept Inc Jun-2023 Quarterly Net Profit is $-4 Million which is growth of 30.9% YoY.

Biocept Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '23Mar '23Dec '22Sep '22Jun '22Mar '22Dec '21Sep '21Jun '21Mar '21Dec '20Sep '20Jun '20
Operating Rev.
0.60.7-10.35.610.619.91417.512.117.818.56.60.9
Cost Of Rev.
2.634.35.8810.31110.37.59105.92.5
Gross Profit
-2-2.4-14.6-0.22.69.637.24.68.88.50.7-1.6
⌄
4.24.745.47.712.36.86.76.36.16.55.64.8
Operating Profit
-6.1-7.1-18.6-5.6-5.1-2.7-3.80.5-1.82.72-4.8-6.4
⌄
-0.1-0.1-0.1-0.1-0.2-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1
Profit Before Tax
-3.6-7.1-18.7-5.5-5.3-2.8-3.90.4-1.82.61.9-4.9-6.5
Tax
-0.10.1
⌄
-3.6-7.1-18.5-5.5-5.3-2.8-40.4-1.82.61.9-4.9-6.5
Diluted NI Avail to Com Stockholders Ann.
-3.6-7.1-18.5-5.5-5.3-2.8-40.4-1.82.61.9-4.9-6.5
Basic EPS
-3.5-12.3-32.7-9.9-9.3-4.8-5.40.9-4.25.74.2-12.9-15
Diluted EPS After ExtraOrdinary
-5.9-12.3-32.7-9.9-9.3-4.8-5.40.9-4.25.74.2-12.9-15
Number Of Shares End
10.60.60.60.60.60.60.50.50.50.50.40.4
Net Income Continuing Discontinued Operations
-3.6-7.1-18.5-5.5-5.3-2.8-40.4-1.82.61.9-4.9-6.5
Normalized Income
-6.1-7.1-18.5-5.5-5.3-2.8-40.4-1.82.61.9-4.9-6.5
Interest Income
-------------
Interest
0.10.10.10.10.20.10.10.10.10.10.10.10.1
Net Interest Income
-0.1-0.1-0.1-0.1-0.2-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1
EBIT
-3.6-7.1-18.6-5.5-5.1-2.7-3.80.5-1.82.72-4.8-6.4
EBITDA
-3.2-6.5-18.2-5.1-5.1-1.9-3.41.3-13.42.2-4.5-6.3
Reconciled Cost Of Rev.
2.634.35.8810.31110.37.59105.92.5
Reconciled Depr.
0.40.60.40.4-00.80.40.80.70.70.30.40.2
Profit From Continuing Operations
-3.6-7.1-18.5-5.5-5.3-2.8-40.4-1.82.61.9-4.9-6.5
Normalized EBITDA
-5.7-6.5-18.2-5.1-5.1-1.9-3.41.3-13.42.2-4.5-6.3
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Biocept Inc competitor comparison and performance snapshot within industry

Biocept Inc annual results: revenue, profit, P&L, and margins as of Dec 2022 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Annual Revenue Biocept Inc Dec-2022 Annual Revenue is $26 Million which is growth of -57.8% YoY.

  • NEGATIVE

    Annual Net Profit Biocept Inc Dec-2022 Annual Net Profit is $-32 Million which is growth of -1036.2% YoY.

Biocept Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15Dec '14Dec '13Dec '12
⌄
67.6%
38.4%
 25.961.327.55.53.35.13.20.60.10.10.1
Cost Of Rev. Ann.
37.2%
24.7%
15.728.437.821.31110.19.46.94.62.22.31.2
Gross Profit Ann.
-
-
-19.1-2.623.56.1-5.5-6.8-4.3-3.7-4-2-2.2-1.1
Operating Exp. Ann.
18.7%
11.7%
18.329.425.921.617.617.516.914.312.411.85.89.4
Operating Profit Ann.
-
-
-37.4-32-2.4-15.5-23.1-24.3-21.2-18-16.4-13.9-7.9-10.5
⌄
-
-
-0.2-0.3-0.3-0.2-0.3-0.3-0.5-0.5-0.6-1.8-2.1-2.2
Other Exp. Ann.
-
0%
 0.1--2.1-1.8-0.10.20.1-0.20.80.4
PBT Ann.
-
-
-35-32.2-2.7-17.8-25.1-24.6-21.6-18.4-17-15.9-9.2-12.3
Tax Ann.
-
-
-0.1-0.10.10
⌄
-
-
-34.8-32.1-2.8-17.8-25.3-25.2-21.6-18.4-17-15.9-9.2-12.3
Diluted NI Avail to Com Stockholders Ann.
-
-
-34.8-32.1-2.8-17.8-25.3-25.2-21.6-18.4-17-15.9-9.2-12.3
EPS Ann.
-
-
 -56.7-5.7-45-366-2,703-7,110.1-17,280.2-23,282.3-96,744.2-55,288.5-73,410.3
Diluted EPS Ann.
-
-
 -56.7-5.7-45-366-2,703-7,110.1-17,280.2-23,282.3-96,744.2-55,288.5-73,410.3
Number Of Shares End
81.7%
-
 0.60.60.50.10
Total Exp. Ann.
26.4%
17.1%
 57.863.742.928.627.526.221.317148.110.6
Net Income Continuing Discontinued Operations Ann.
-
-
-34.8-32.1-2.8-17.8-25.1-24.6-21.6-18.4-17-15.9-9.2-12.3
Normalized Income Ann.
-
-
-37.3-32.1-2.8-15.7-23.3-24.6-21.6-18.5-17-15.7-9.7-12.6
Interest Income Ann.
-
-
 -----------
Interest Ann.
-
-
0.20.30.30.2------2.12.2
EBITDA Ann.
-
-
-32.9-30.20.2-16.6-22.3-23.5-20.6-17.7-16.2-13.6-6.9-9.7
Reconciled Cost Of Rev. Ann.
37.2%
24.7%
15.728.437.821.31110.19.46.94.62.22.31.2
Reconciled Depr. Ann.
28.6%
23.2%
1.81.72.610.80.80.60.30.30.30.30.4
Profit From Continuing Operations Ann.
-
-
-34.8-32.1-2.8-17.8-25.1-24.6-21.6-18.4-17-15.9-9.2-12.3
Normalized EBITDA Ann.
-
-
-35.4-30.20.2-14.5-20.5-23.5-20.7-17.9-16.3-13.4-7.7-10.2
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
-57.7%
2Y CAGR
-3%
3Y CAGR
67.6%
5Y CAGR
38.4%
7Y CAGR
71.2%
10Y CAGR
74.3%
Total Revenue Annual is falling faster than historical averages.
Operating Exp. Ann.
1Y CHG
13.5%
2Y CAGR
16.7%
3Y CAGR
18.7%
5Y CAGR
11.7%
7Y CAGR
13.1%
10Y CAGR
12.1%
Operating Expenses Annual Cr growth is stable compared to historical averages.

Biocept Inc balance sheet as of Dec 2022: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Total Shareholders Fund Biocept Inc Dec-2022 Total Shareholders Fund is $9 Million which is growth of -76.4% YoY.

  • NEGATIVE

    Total Assets Biocept Inc Dec-2022 Total Assets is $31 Million which is growth of -48.9% YoY.

Biocept Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15Dec '14Dec '13Dec '12
⌄
20.4%
33.1%
30.960.447.517.78.87.47.610.66.61.31.5
⌄
50.1%
29.2%
2222.923.86.55.76.16.96.96.813.828.9
⌄
-7.4%
46.9%
8.937.523.711.231.30.73.7-0.2-12.5-27.4
Total Capitalization Ann.
-7.4%
46.9%
8.937.523.711.231.31.86.34.5-12.5-26.6
Tangible Assets Ann.
-7.4%
46.9%
8.937.523.711.231.30.73.7-0.2-12.5-27.4
Working Capital Ann.
9.2%
-
10.833.920.18.31.4-0.41.46.34.5-12.4-27
Invested Capital Ann.
-7%
29.2%
937.523.711.232.53.77.94.5-5.3-4.8
Tangible Book Value Ann.
-7.4%
46.9%
8.937.523.711.231.30.73.7-0.2-12.5-27.4
Borrowings Ann.
69.2%
35%
12.112.712.22.51.62.73.34.64.97.222.6
Net Debt Ann.
-
-
---------7.122.4
Share Issued Ann.
44.2%
-
0.60.60.50.20
Number Of Shares End
81.7%
-
0.60.60.50.10
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-48.8%
2Y CAGR
-19.3%
3Y CAGR
20.4%
5Y CAGR
33.1%
7Y CAGR
16.5%
10Y CAGR
35.3%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
-53.4%
2Y CAGR
-33.7%
3Y CAGR
-0.6%
5Y CAGR
3.2%
7Y CAGR
7.6%
10Y CAGR
-14.9%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-76.3%
2Y CAGR
-38.7%
3Y CAGR
-7.4%
5Y CAGR
46.9%
7Y CAGR
13.4%
Total ShareHolders Funds Annual is falling faster than historical averages.

Biocept Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2022 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Biocept Inc Book Value Per Share is $0 which is growth of -99.8% YoY.

  • POSITIVE

    ROE Biocept Inc ROE is -138% which is growth of 129.3% YoY.

Biocept Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15Dec '14Dec '13Dec '12
RoA Ann. %
-
-
-70.30%-5.24%-54.64%-190.76%-312.58%-289.01%-202.58%-197.37%-400.76%-659.65%-694.75%
ROE Ann. %
-
-
-138.49%-9.23%-102.08%-354.69%-1,162.05%-2,211.47%-845.67%-976.31%---
ROIC %
-
-
-60.8-7.76.6-46.7-79.2-101.6--45.7-60.3--
OPM Ann. %
-
-
-123.69%-3.93%-56.33%-417.05%-746.35%-417.76%-559.25%-2,690.69%-10,398.68%-5,917.64%-9,610.28%
Inventory Turnover Ratio Ann.
1%
-1.3%
16.716.515.816.218.517.815.417.115.430.239.2
Asset Turnover Ann. %
14.5%
-3%
0.61.10.80.40.40.70.40.100.10.1
Working Capital Turnover Ann.
50.8%
-
2.41.81.40.72.3-12.52.30.10-0
Quick Ratio Ann.
5.5%
31%
2.73.62.32.31.10.71.12.73.800
Current Ratio Ann.
6.3%
27.2%
33.92.62.51.30.91.32.94.10.10
Interest Coverage Ratio Ann.
-
-
-100.9-8.3-74.3-------3.5-4.6
LT Debt To Equity Ann.
128.9%
5.9%
1.20.30.50.10.30.91.70.8---
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Current Ratio Ann.
1Y CHG
-23.1%
2Y CAGR
7.4%
3Y CAGR
6.3%
5Y CAGR
27.2%
7Y CAGR
0.5%
Current Ratio Annual is falling faster than historical averages.

Biocept Inc cash flow: net, operating, investing, and financing flows as of Dec 2022 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Biocept Inc Dec-2022 Cash From Operating Activity is $-13 Million which is growth of -460.1% YoY.

  • NEGATIVE

    Net Cash Flow Biocept Inc Dec-2022 Net Cash Flow is $-16 Million which is growth of -210.1% YoY.

Biocept Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15Dec '14Dec '13Dec '12
⌄
-
-
-13.33.7-19.8-23.1-22.4-19.7-15.7-15.2-14.6-6.2-8.6
⌄
-
-
-0.8-1.6-0.9-0.7-0.2-1.4-0.5-0.2-0.4-0
⌄
-
-
-1.912.425.729.723.818.611.918.820.36.18.4
Cash Plus Cash Eqv. End Of Year Ann.
11.5%
42.4%
12.928.914.49.33.42.24.68.85.40.10.2
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-1614.55.15.91.3-2.5-4.23.55.3-0.1-0.3
Cash Plus Cash Eqv. Begin Of Year Ann.
104.1%
44.4%
28.914.49.33.42.24.68.85.40.10.20.4
Income Tax Paid Supplemental Data Ann.
-
-
-0
Interest Paid Supplemental Data Ann.
0%
-5.6%
0.30.30.20.30.60.40.40.40.40
Capex Ann.
-
-
-0.8-1.6-0.9-0.7-0.2-1.4-0.5-0.2-0.4-0
Issuance Of Capital Stock Ann.
-80.2%
-56.9%
0.214.124.225.725.713.513.89.817.4--
Issuance Of Debt Ann.
-
-
----0.2--5.56.28.5
Repayment Of Debt Ann.
-
-
-1.3-1.2-0.7-0.5-1.4-2.1-1.2-0.6-2.4-
Repurchase Of Capital Stock Ann.
-
-
--------
Free Cash Flow Ann.
-
-
-14.12.1-20.7-23.8-22.5-21.1-16.2-15.3-15-6.2-8.6
*All financials are in USD Million and price data in USD
Add metric to table
Search...
×